Who are Peginterferon α2b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PegIFN-2b, Pegyinterferon-alfa-2a, pegylated interferon-alfa, B: Peg-interferon alpha-2a & Ribavirin, Peginterferon alfa-2a + ribavirin, Low-dose anrikefon.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peginterferon-2b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peginterferon α2b — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peginterferon α2b (Peginterferon α2b) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Infectious Diseases.

phase 3 Interferon IFNAR Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Peginterferon α2b (Peginterferon α2b) — University of Jena. Peginterferon α2b works by stimulating the body's immune system to fight viral infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Peginterferon α2b TARGET	Peginterferon α2b	University of Jena	phase 3	Interferon	IFNAR
PegIFN-2b	PegIFN-2b	Merck Sharp & Dohme LLC	marketed	Pegylated interferon-beta	Interferon-beta receptor (IFNAR)
Pegyinterferon-alfa-2a	Pegyinterferon-alfa-2a	Chinese University of Hong Kong	marketed	Pegylated interferon	Interferon-alfa receptor (IFNAR)
pegylated interferon-alfa	pegylated interferon-alfa	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Interferon	Interferon-alfa receptor (IFNAR)
B: Peg-interferon alpha-2a & Ribavirin	B: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase
Peginterferon alfa-2a + ribavirin	Peginterferon alfa-2a + ribavirin	Hospital Clinico Universitario San Cecilio	marketed	Interferon alpha + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Low-dose anrikefon	Low-dose anrikefon	Peking University First Hospital	marketed	Interferon-alpha analog	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peginterferon α2b — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-2b. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing